AxSpA outcome measures in relation to IBS status
| No IBS symptoms* (n=127) | IBS symptoms* (n=55) | P value† | |
| VAS global, mm | 30 (25) | 44 (25) | 0.010 |
| VAS pain, mm | 30 (26) | 43 (26) | 0.020 |
| VAS fatigue, mm | 32 (27) | 50 (27) | 0.001 |
| EQ-5D utility‡ | 0.75 (0.22) | 0.61 (0.30) | 0.004 |
| BASDAI | 2.6 (2.1) | 4.3 (2.1) | <0.001 |
| BASFI | 1.8 (2.2) | 2.9 (2.2) | 0.016 |
| BASMI | 3.1 (1.6) | 2.8 (1.4) | 0.609 |
| Evaluator’s VAS global, mm | 16 (14) | 19 (14) | 0.569 |
Values are mean (SD). Missing data, n (%): VAS global/pain/fatigue 5 (3%), EQ-5D 12 (7%), BASDAI 12 (7%), BASFI 16 (9%), BASMI 4 (2%), Evaluator’s VAS global 11 (6%).
*Assessed by the ROME III questionnaire.
†Adjusted for sex and age by analysis of covariance.
‡UK time trade-off based preference set.
AxSpA, axial spondyloarthritis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; BASMI, Bath ankylosing spondylitis metrology index; EQ-5D, EuroQol 5-Dimensions; IBS, irritable bowel syndrome; VAS, visual analogue scale.